Methods for reducing infusion-related reactions in patients treated with EGFR / met bispecific antibodies
TW202629606APending Publication Date: 2026-07-16JANSSEN BIOTECH INC
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- TW114130925
- Authority / Receiving Office
- TW · TW
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-09-09
- Filing Date
- 2025-08-13
- Publication Date
- 2026-07-16
Abstract
The present invention relates to methods of reducing occurrence or severity of infusion-related reactions (IRRs) in a subject treated with an anti-epidermal growth factor receptor (EGFR) / hepatocyte growth factor receptor (c-Met) antibody, comprising administering (a) dexamethasone; (b) montelukast; or (c) methotrexate to the subject.
Need to check novelty before this filing date? Find Prior Art